Neurocrine Biosciences | NBIX - 现金及等价物



金融业
股票价格
USD
资产
USD 4.91B
现金及等价物
USD 266.5M
销售成本
USD 13.8M
流动资产
USD 2.44B
流动负债
USD 831.7M
债务
USD 406.2M
EBIT
USD 214.6M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 1.94
股本和储备
USD 3.41B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 17.34B
净收入
USD 197.9M
营业费用
USD 599.9M
营业利润
USD 214.6M
普通股股本
USD 100.6M
PE价格收益
28.09
税前利润
USD 246.8M
销售收入
USD 811M
销售和管理费用
USD 318.5M
股票
USD 64.5M
贸易债权人
USD 691.3M
应收帐款人
USD 768.1M


现金及等价物 更改 日
AbbVie USD 9.39B 4.16B 2026-03
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Cytokinetics USD 129.84M 7.32M 2026-03
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Exelixis USD 226.15M 256.34M 2026-03
Gilead Sciences USD 7.56B 234M 2025-12
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Incyte USD 4.02B 435.22M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Pfizer USD 1.7B 561M 2026-03
Prothena USD 329.46M 21.93M 2026-03
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Repligen USD 582.65M 16.63M 2026-03
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03
Xoma USD 143.9M 7.68M 2024-06